ID   KCI-MOH1
AC   CVCL_2090
SY   KciMoh-1; KCIMOH1; WSU-MOH1
DR   EFO; EFO_0006608
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03151779
DR   CCLE; KCIMOH1_PANCREAS
DR   DepMap; ACH-001098
DR   DSMZ; ACC-498
DR   GEO; GSM887201
DR   GEO; GSM888274
DR   PharmacoDB; KCIMOH1_738_2019
DR   Wikidata; Q54899646
RX   CelloPub=CLPUB00416;
RX   PubMed=9436858;
RX   PubMed=15770730;
RX   PubMed=20143388;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=26216984;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://iclac.org/wp-content/uploads/Cross-Contaminations_v9_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HPAC derivative (PubMed=20143388). Originally thought to originate from a 74 year old male patient with a moderately differentiated adenocarcinoma of the head of the pancreas.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00322.
CC   Doubling time: ~70 hours (DSMZ).
CC   Sequence variation: CDKN2A p.Glu120Ter (c.358G>T) (from parent cell line).
CC   Sequence variation: KRAS p.Gly12Asp (c.35G>A) (from parent cell line).
CC   Omics: Deep RNAseq analysis.
CC   Omics: Metabolome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.11%; East Asian, North=2.33%; East Asian, South=0%; South Asian=0%; European, North=65.07%; European, South=32.5% (PubMed=30894373).
CC   Discontinued: BioIVT/Asterand Bioscience; Catalog number WSU-MOH1.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 11
ST   D16S539: 9,10
ST   D5S818: 12
ST   D7S820: 10,12
ST   TH01: 9.3
ST   TPOX: 10,11
ST   vWA: 15,17
DI   NCIt; C8294; Pancreatic adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_3517 ! HPAC
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 24
//
RX   CelloPub=CLPUB00416;
RA   Oberlin L.;
RT   "Treatment of pancreatic carcinoma cell lines in vitro and vivo with a
RT   monoclonal antibody against the transferrin receptor.";
RL   Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany.
//
RX   PubMed=9436858; DOI=10.1097/00006676-199801000-00004;
RA   Mohammad R.M., Dugan M.C., Mohamed A.N., Almatchy V.P., Flake T.M.,
RA   Dergham S.T., Shields A.F., Al-Katib A., Vaitkevicius V.K.,
RA   Sarkar F.H.;
RT   "Establishment of a human pancreatic tumor xenograft model: potential
RT   application for preclinical evaluation of novel therapeutic agents.";
RL   Pancreas 16:19-25(1998).
//
RX   PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521;
RA   Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W.,
RA   Marten A.;
RT   "Synergistic effects of interferon-alpha in combination with
RT   chemoradiation on human pancreatic adenocarcinoma.";
RL   World J. Gastroenterol. 11:1521-1528(2005).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//